Jeffrey Pott - AstraZeneca PLC General Counsel
| AZNCF Stock | USD 125.50 0.80 0.64% |
Executive
Mr. Jeffrey A. Pott is General Counsel of AstraZeneca Plc. He was appointed General Counsel in January 2009 and has overall responsibility for all aspects of AstraZenecas Legal and IP function. He joined AstraZeneca in 1995 and has worked in various litigation roles, where he has had responsibility for IP, antitrust and product liability litigation. Before joining AstraZeneca, he spent five years at the US legal firm Drinker Biddle and Reath LLP, where he specialised in pharmaceutical product liability litigation and antitrust advice and litigation. He received his bachelors degree in political science from Wheaton College and his Juris Doctor Degree from Villanova University School of Law. since 2009.
| Tenure | 15 years |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Thomas Larsen | Sanofi ADR | 50 | |
| Pierre Chancel | Sanofi ADR | 67 | |
| Madeleine Roach | Sanofi ADR | 40 | |
| Lluis Gomez | Grifols SA ADR | 41 | |
| Kenji Yasukawa | Astellas Pharma | 63 | |
| Vasant Narasimhan | Novartis AG | 47 | |
| Cristina Wilbur | Roche Holding AG | 56 | |
| FranoisXavier Roger | Sanofi ADR | 62 | |
| Cristina Wilbur | Roche Holding AG | 56 | |
| Alan Hippe | Roche Holding Ltd | 56 | |
| Klaus Moosmayer | Novartis AG | 55 | |
| Roy Papatheodorou | Sanofi ADR | 46 | |
| Raimon Roura | Grifols SA ADR | 60 | |
| Harry Kirsch | Novartis AG | 58 | |
| Camille Alpi | Grifols SA ADR | 43 | |
| Natalie Bickford | Sanofi ADR | 54 | |
| Heiko Schipper | Bayer AG | 54 | |
| Werner Baumann | Bayer AG | 61 | |
| Stefan Oelrich | Bayer AG | 55 | |
| Kenji Yasukawa | Astellas Pharma | 63 | |
| Cristina Wilbur | Roche Holding Ltd | 56 | |
Management Performance
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 |
AstraZeneca PLC Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, CFO and Executive Director | ||
| Chris Sheldon, Head Relations | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| MBA DVM, CEO Director | ||
| Gonzalo Vina, Head Relations | ||
| Aradhana MD, CFO Director | ||
| Menelas Pangalos, Executive Vice President - Innovative Medicines | ||
| Katarina Ageborg, Chief Compliance Officer | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President Europe |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 241.1 B | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 48.84 % | |||
| Price To Earning | 44.18 X | |||
| Price To Book | 6.16 X |
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Pink Sheet
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.